The US Court of Appeals for the Federal Circuit affirmed a district court’s delisting of patents from the Orange Book because the patent claims ...

On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

The manufacturers' reported dose per actuation for both MDIs is 108 µg of albuterol sulfate ... of the inhalers when not allowed to return to room temperature. Proventil HFA and Ventolin HFA ...

Amneal beats Teva’s challenge of ruling on some ProAir patents Decision could impact other ‘junk device listings,’ FTC says Five patents related to Teva Pharmaceutical Industries Ltd.’s ProAir HFA ...

ProAir HFA inhaler from the Food and Drug Administration’s Orange Book. Amneal plans to market a generic version of the inhaler and had argued that Teva’s patents were incorrectly included on ...